Naringenin demonstrated synergistic effects with paclitaxel, enhancing its ability to induce apoptosis by modulating the PI3K/AKT pathway and inhibiting ERK1/2, p38, and JNK in the PC-3 prostate cancer cells. The gene discussed is AKT1; the disease is prostate carcinoma.